The inherited retinal disease (IRD) community is buzzing with the news that Editas Medicine is set to present new data on its gene editing programs. This update from the company, a leader in genome editing, offers a glimpse into the ongoing advancements that could one day lead to transformative treatments for conditions causing severe vision loss.
Editas Medicine announced on April 30, 2018, that ten scientific abstracts, including three from research collaborations, were accepted for presentation at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). The meeting was scheduled to take place from May 16-19 in Chicago. These presentations highlight the company's commitment to advancing its pipeline and platform technologies, particularly in areas relevant to the IRD community.
Key data to be presented include findings related to EDIT-101, an experimental medicine targeting Leber Congenital Amaurosis type 10 (LCA10). The data showed that EDIT-101, when administered to non-human primates via subretinal injection, was well-tolerated. Furthermore, therapeutically relevant editing levels were observed in these primates, regardless of pre-existing immunity to Staphylococcus aureus Cas9. The specificity of EDIT-101 was also highlighted, with no verified off-target effects in the human genome.
Beyond LCA10, Editas Medicine also shared news of in vitro validation for an exon deletion editing strategy with the potential to treat Usher Syndrome type 2a (USH2A)-associated retinal disease. This indicates a broader application of their gene editing technology to address various forms of IRDs. Charles Albright, Ph.D., Chief Scientific Officer at Editas Medicine, emphasized the significant scientific advances being made to unlock the potential of CRISPR genome editing for developing medicines.
For patients and families affected by IRDs, these developments represent continued progress in the quest for effective treatments. While these are early findings, particularly in non-human primate studies and in vitro models, they lay crucial groundwork for future clinical trials. The focus on conditions like LCA10 and Usher Syndrome type 2a offers hope that gene editing could one day provide durable solutions for inherited vision loss.
Editas Medicine aims to translate the power of CRISPR genome editing into a robust pipeline of treatments for serious diseases. The company's ongoing research and presentations at significant scientific conferences underscore the dynamic nature of gene therapy development. The IRD community will be watching closely as these promising technologies continue to advance towards clinical application.